Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)

Author's Avatar
Jan 04, 2023

HALIFAX, NS / ACCESSWIRE / January 3, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR, Financial) announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection - (available: %3Cu%3Ehttps%3A%2F%2Fwww.mdpi.com%2F2076-0817%2F12%2F1%2F77%3C%2Fu%3E), in the special edition of Pathogens by MDPI, a Swiss based medical journal. The article written by Professor John Alderete from the School of Molecular Biosciences, Washington State University, outlines the successful development of a POC diagnostic device for Trichomonas vaginalis based on MedMira's RVF Technology®.